Neurology 2003;61:479-486
© 2003 American Academy of Neurology
Donepezil in vascular dementia
A randomized, placebo-controlled study
D. Wilkinson, MBChB MRCGP, FRCPsych,
R. Doody, MD PhD,
R. Helme, MBBS PhD, FRACP, FFPMANZCA,
K. Taubman, MBBS FRACP,
J. Mintzer, MD,
A. Kertesz, MD and
R.D. Pratt, MD the Donepezil 308 Study Group*
From Memory Assessment and Research Centre (Dr. Wilkinson), Moorgreen Hospital, Southampton, UK; Alzheimer’s Disease Center (Dr. Doody), Baylor College of Medicine, Houston, TX; National Ageing Research Institute (Dr. Helme), Parkville, Victoria, Australia; Austin and Repatriation Medical Centre (Dr. Taubman), Heidelberg, Victoria, Australia; Medical University of South Carolina (Dr. Mintzer), Alzheimer’s Research and Clinical Programs, North Charleston, SC; University of Western Ontario (Dr. Kertesz), St. Joseph’s Hospital, London, Ontario, Canada; and Eisai Inc. (Dr. Pratt), Teaneck, NJ.
Address correspondence and reprint requests to Dr. David Wilkinson, Memory Assessment and Research Centre, Moorgreen Hospital, Southampton SO30 3JB, UK; e-mail: david.wilkinson{at}wht.nhs.uk
Objective: To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD).
Methods: Patients (n = 616; mean age, 75.0 years) with probable or possible VaD, according to National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche en l’Enseignement en Neurosciences criteria, were randomized to receive donepezil 5 mg/day (n = 208), donepezil 10 mg/day (after 5 mg/day for the first 28 days) (n = 215), or placebo (n = 193) for 24 weeks.
Results: Seventy-six percent of the patients enrolled had probable VaD. A total of 75.3% of the 10 mg donepezil group and 80.8% of the 5 mg group completed the study compared with 83.4% of the placebo group. Both donepezil-treated groups showed improvements in cognitive function on the Alzheimer’s Disease Assessment Scale–cognitive subscale compared with placebo, with a mean endpoint treatment difference, as measured by the change from baseline score, of approximately 2 points (donepezil 5 mg, -1.65 [p = 0.003]; 10 mg, -2.09 [p = 0.0002]). Greater improvements on the Clinician’s Interview-Based Impression of Change–plus version were observed with both donepezil groups than with the placebo group (overall donepezil treatment vs placebo p = 0.008); 25% of the placebo group showed improvement compared with 39% (p = 0.004) of the 5 mg group and 32% (p = 0.047) of the 10 mg group. Withdrawal rates due to adverse events were low (placebo, 8.8%; donepezil 5 mg, 10.1%; 10 mg, 16.3%).
Conclusions: Donepezil-treated patients demonstrated significant improvements in cognition and global function compared with placebo-treated patients, and donepezil was well tolerated.
This article has been cited by other articles:
|
|
|
|
 
R. E. Jorge, L. Acion, D. Moser, H. P. Adams Jr, and R. G. Robinson
Escitalopram and Enhancement of Cognitive Recovery Following Stroke
Arch Gen Psychiatry,
February 1, 2010;
67(2):
187 - 196.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Jay Cheol Kwon, Eung Gyu Kim, Jae Woo Kim, Oh Dae Kwon, Bong Goo Yoo, Hyon Ah Yi, Nack Cheon Choi, Seon Young Ahn, Byung Hwa Lee, Myong Jin Kang, et al.
A Multicenter, Open-Label, 24-Week Follow-Up Study for Efficacy on Cognitive Function of Donepezil in Binswanger-Type Subcortical Vascular Dementia
American Journal of Alzheimer's Disease and Other Dementias,
August 1, 2009;
24(4):
293 - 301.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. H Rojas-Fernandez and P. Moorhouse
Current Concepts in Vascular Cognitive Impairment and Pharmacotherapeutic Implications
Ann. Pharmacother.,
July 1, 2009;
43(7):
1310 - 1323.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Poon, L. S Lal, M. E Ford, and U. K Braun
Racial/Ethnic Disparities in Medication Use Among Veterans with Hypertension and Dementia: A National Cohort Study
Ann. Pharmacother.,
February 1, 2009;
43(2):
185 - 193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Viswanathan, W. A. Rocca, and C. Tzourio
Vascular risk factors and dementia: How to move forward?
Neurology,
January 27, 2009;
72(4):
368 - 374.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Qaseem, V. Snow, J. T. Cross Jr., M. A. Forciea, R. Hopkins Jr., P. Shekelle, A. Adelman, D. Mehr, K. Schellhase, D. Campos-Outcalt, et al.
Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians
Ann Intern Med,
March 4, 2008;
148(5):
370 - 378.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, M. Levine, L. Booker, and M. Oremus
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Ann Intern Med,
March 4, 2008;
148(5):
379 - 397.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Modrego, C. Rios, J. M. Perez Trullen, J. M. Errea, M. J. Garcia-Gomara, and S. Sanchez
The Cerebrovascular Pathology in Alzheimer's Disease and Its Influence on Clinical Variables
American Journal of Alzheimer's Disease and Other Dementias,
March 1, 2008;
23(1):
91 - 96.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. A. Schneider, Z. Arvanitakis, W. Bang, and D. A. Bennett
Mixed brain pathologies account for most dementia cases in community-dwelling older persons
Neurology,
December 11, 2007;
69(24):
2197 - 2204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Auchus, H. R. Brashear, S. Salloway, A. D. Korczyn, P. P. De Deyn, C. Gassmann-Mayer, and For the GAL-INT-26 Study Group
Galantamine treatment of vascular dementia: A randomized trial
Neurology,
July 31, 2007;
69(5):
448 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Burns and J. O'Brien
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
J Psychopharmacol,
November 1, 2006;
20(6):
732 - 755.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. R. Farlow
Use of Antidementia Agents in Vascular Dementia: Beyond Alzheimer Disease
Mayo Clin. Proc.,
October 1, 2006;
81(10):
1350 - 1358.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Knopman
Dementia and Cerebrovascular Disease
Mayo Clin. Proc.,
February 1, 2006;
81(2):
223 - 230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Langa, N. L. Foster, and E. B. Larson
Mixed Dementia: Emerging Concepts and Therapeutic Implications
JAMA,
December 15, 2004;
292(23):
2901 - 2908.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Krupp, C. Christodoulou, P. Melville, W. F. Scherl, W. S. MacAllister, and L. E. Elkins
Donepezil improved memory in multiple sclerosis in a randomized clinical trial
Neurology,
November 9, 2004;
63(9):
1579 - 1585.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. S. Sachdev, H. Brodaty, M. J. Valenzuela, L. Lorentz, and A. Koschera
Progression of cognitive impairment in stroke patients
Neurology,
November 9, 2004;
63(9):
1618 - 1623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K Rockwood
Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease
J. Neurol. Neurosurg. Psychiatry,
May 1, 2004;
75(5):
677 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Erkinjuntti, G. Roman, S. Gauthier, H. Feldman, and K. Rockwood
Emerging Therapies for Vascular Dementia and Vascular Cognitive Impairment
Stroke,
April 1, 2004;
35(4):
1010 - 1017.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Bowler
Vascular Cognitive Impairment
Stroke,
February 1, 2004;
35(2):
386 - 388.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Donepezil for Vascular Dementia
Journal Watch Psychiatry,
November 20, 2003;
2003(1120):
17 - 17.
[Full Text]
|
|
|
|
|
|
|
S. Black, G. C. Roman, D. S. Geldmacher, S. Salloway, J. Hecker, A. Burns, C. Perdomo, D. Kumar, and R. Pratt
Efficacy and Tolerability of Donepezil in Vascular Dementia: Positive Results of a 24-Week, Multicenter, International, Randomized, Placebo-Controlled Clinical Trial
Stroke,
October 1, 2003;
34(10):
2323 - 2330.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Donepezil for Vascular Dementia
Journal Watch (General),
September 26, 2003;
2003(926):
1 - 1.
[Full Text]
|
|
|
|
